Iovance Biotherapeutics Inc [NASDAQ: IOVA] stock went on an upward path that rose over 0.57% on Monday, amounting to a one-week price decrease of less than -1.12%.
Over the last 12 months, IOVA stock dropped by -81.03%. The one-year Iovance Biotherapeutics Inc stock forecast points to a potential upside of 83.55. The average equity rating for IOVA stock is currently 1.75, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $587.73 million, with 333.93 million shares outstanding and 271.58 million shares in the current float. Compared to the average trading volume of 12.85M shares, IOVA stock reached a trading volume of 9027220 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Iovance Biotherapeutics Inc [IOVA]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for IOVA shares is $10.70 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on IOVA stock is a recommendation set at 1.75. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
UBS have made an estimate for Iovance Biotherapeutics Inc shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on May 16, 2025. The new note on the price target was released on May 12, 2025, representing the official price target for Iovance Biotherapeutics Inc stock.
The Average True Range (ATR) for Iovance Biotherapeutics Inc is set at 0.21, with the Price to Sales ratio for IOVA stock in the period of the last 12 months amounting to 2.76. The Price to Book ratio for the last quarter was 0.77, with the Price to Cash per share for the same quarter was set at 1.08.
IOVA Stock Performance Analysis:
Iovance Biotherapeutics Inc [IOVA] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -1.12. With this latest performance, IOVA shares dropped by -47.15% in over the last four-week period, additionally sinking by -80.70% over the last 6 months – not to mention a drop of -81.03% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for IOVA stock in for the last two-week period is set at 33.94, with the RSI for the last a single of trading hit 34.70, and the three-weeks RSI is set at 34.17 for Iovance Biotherapeutics Inc [IOVA]. The present Moving Average for the last 50 days of trading for this stock 2.8242, while it was recorded at 1.7640 for the last single week of trading, and 6.8169 for the last 200 days.
Insight into Iovance Biotherapeutics Inc Fundamentals:
Iovance Biotherapeutics Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 3.64 and a Current Ratio set at 4.18.
IOVA Stock EPS
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for IOVA. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Iovance Biotherapeutics Inc go to 47.62%.
Iovance Biotherapeutics Inc [IOVA] Institutonal Ownership Details
The top three institutional holders of IOVA stocks are: VANGUARD GROUP INC with ownership of 25.95 million shares, which is approximately 9.1113%. PERCEPTIVE ADVISORS LLC, holding 25.93 million shares of the stock with an approximate value of $$207.98 million in IOVA stocks shares; and PERCEPTIVE ADVISORS LLC, currently with $$192.46 million in IOVA stock with ownership which is approximately 8.4254%.
